Treatment of generalized anxiety disorder

Journal of Clinical Psychiatry

Volumn 63, Issue SUPPL. 8, 2002, Pages 17-23

  Gorman, Jack M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DELORAZEPAM; IMIPRAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANXIETY NEUROSIS; ARTICLE; COGNITIVE DEFECT; CONSTIPATION; DRUG EFFICACY; EDEMA; HUMAN; HYPOTENSION; MOTOR DYSFUNCTION; NAUSEA; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; SEDATION; SEXUAL DYSFUNCTION; SLEEP DISORDER; TREATMENT INDICATION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; BENZODIAZEPINES; BUSPIRONE; CLINICAL TRIALS; COGNITIVE THERAPY; CYCLOHEXANOLS; FOLLOW-UP STUDIES; HUMANS; PAROXETINE; PSYCHOTHERAPY; PYRIMIDINES; RELAXATION TECHNIQUES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0036090621     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey
2. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys
3. Prevalence and recognition of anxiety syndromes in five European primary care settings: A report from the WHO study on Psychological Problems in General Health Care
4. Neurotic disorders and the receipt of psychiatric treatment
5. Factors predicting the clinical course of generalized anxiety disorder
6. Clinical guidelines for establishing remission in patients with depression and anxiety
7. Cognitive theories of generalized anxiety disorder
8. Explicit memory bias for threat words in generalized anxiety disorder
9. Further tests of a cognitive model of generalized anxiety disorder: Metacognitions and worry in GAD, panic disorder, social phobia, depression and nonpatients
10. Recovery rates in generalized anxiety disorder following psychological therapy: An analysis of clinically significant change in the STAI-T across outcome studies since 1990
11. The nonpharmacologic treatment of generalized anxiety disorder
12. Effektivität psychologischer therapien von generalisierter angstörung und sozialer phobie: Meta-analysen auf störungsebene
13. Generalized anxiety disorder: An important clinical concern
14. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: Evaluation in a controlled clinical trial
15. The interaction of drug- and psychotherapy in the long-term treatment of depression
16. Neurobiologic basis of anxiety and its treatment
17. Long-term diazepam therapy and clinical outcome
18. Clorazepate and lorazepam: Clinical improvement and rebound anxiety
19. Long-term treatment of anxiety and risk of withdrawal: Prospective comparison of clorazepate and buspirone
20. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone, and diazepam
21. Use of benzodiazepines in anxiety disorders
22. Drug therapy: Current status of benzodiazepines
23. Alprazolam compared to clobazam and placebo in anxious outpatients
24. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder
25. A comparative study of suriclone, lorazepam and placebo in anxiety disorder
26. Buspirone and diazepam in anxiety: A controlled study
27. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms
28. Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder
29. Paroxetine efficacy in the treatment of generalized anxiety disorder
30. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder
31. Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients
32. Subchronic effects of the GABA-agonist lorazepam and the 5-HT2A/2C antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers
33. Hazardous benzodiazepine regimens in the elderly: Effects of half-life, dosage, and duration on risk of hip fracture
34. Clinical aspects of chronic use of alprazolam and lorazepam
35. The functional anatomy, neurochemistry, and pharmacology of anxiety
36. Gradual withdrawal of diazepam after long-term therapy
37. Double-blind comparison of buspirone and clorazepate in anxious outpatients
38. Serotonin agents in anxiety
39. Comparison of buspitone and diazepam in generalized anxiety disorder
40. Buspirone in the long-term treatment of generalized anxiety disorder
41. Evaluation of buspirone as an antianxiety agent: Buspirone and diazepam versus placebo
42. Controlled comparison of buspirone and oxazepam in generalized anxiety
43. A double-blind, controlled trial in primary care patients with generalized anxiety: A comparison between buspirone and oxazepam
44. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder
45. Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety
46. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients
47. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: A prospective multicenter trial
48. A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder
49. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder
50. Gepirone and diazepam in generalized anxiety disorder: A placebo-controlled trial
51. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder
52. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder
53. Pharmacologic treatments effective in both generalized anxiety disorder and major depressive disorder: Clinical and theoretical implications
54. Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use
55. Pharmacologic treatment of anxiety disorders in 1989 versus 1996: Results from the Harvard/Brown Anxiety Disorders Research Program
56. Imipramine and chlordiazepoxide in depressive and anxiety disorders, 2: Efficacy in anxious outpatients
57. Pharmacology of antidepressants-characteristics of the ideal drug
58. Adverse effects of antidepressant drugs, pt 1: Monoamine oxidase inhibitors and tricyclics
59. A naturalistic study of imipramine in panic disorder and agoraphobia
60. Contemporary management of depression
61. Antidepressants in long-term therapy: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors
62. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors
63. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexibledosage trial
64. Changes on the Temperament and Character Inventory after paroxetine treatment in volunteers with generalized anxiety disorder
65. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders
66. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
67. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder
68. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder
69. Characterization of the longitudinal course of longterm venlafaxine ER treatment of GAD
70. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: Pooled analysis of five randomized placebo-controlled clinical trials
71. Effexor (venlafaxine). Physicians' Desk Reference
72. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study
73. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial
74. Efficacy of venlafaxine ER in social adjustment in patients with generalized anxiety disorder
75. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder
76. Abecarnil for the treatment of generalized anxiety disorder: A placebo-controlled comparison of two dosage ranges of abecarnil and buspirone
77. Abecarnil, a new beta-carboline, in the treatment of anxiety disorders
78. A double-blind, placebocontrolled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder
79. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder
80. Kava-kava-extrakt überzeugt bei generalisierter angst
81. Recent clinical trials of hydroxyzine in generalized anxiety disorder
82. Opipramol for the treatment of generalized anxiety disorder: A placebo-controlled trial including an alprazolam-treated group
83. An open trial of nefazodone in adult patients with generalized anxiety disorder
84. Response of anxiety and agitation symptoms during nefazodone treatment of major depression
85. The effect of nefazodone on comorbid anxiety symptoms associated with depression: Experience in family practice and psychiatric outpatient settings